2025 Q3 -tulosraportti
91 päivää sitten
‧23 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
3 654
Myynti
Määrä
13 890
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 346 | - | - | ||
| 250 | - | - | ||
| 5 676 | - | - | ||
| 32 000 | - | - | ||
| 10 000 | - | - |
Ylin
0,992VWAP
Alin
0,962VaihtoMäärä
0,1 152 552
VWAP
Ylin
0,992Alin
0,962VaihtoMäärä
0,1 152 552
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 141 176 | 141 176 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 141 176 | 141 176 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·13.2.Anyone who is optimistic about bioporto right now? Have been in for over 5 years and have a loss of 75 percent. Feel it's the next one I'll take the loss on, if others agree.
·12.2.The stock price, I think, will probably soon be kr. 4,032. But we'll see in the next couple of months.
·14.2. · MuokattuIf we look at the last automatic analysis, the signal is that shareholders are a bit pessimistic about this stock, it justifies this by stating that it closed yesterday below one krone. My opinion is that this fits very well, because the new duo must prove their worth and deliver positive results to gain the shareholders' trust. The positive thing is that I can get more shares for cheaper money. Although it is early in the journey, the results and new expectations for 2026 continue to confirm the execution of the "Fremadrettet" strategy. BioPorto aims for a total revenue of DKK 48-58 million for 2026 (growth of 20-45%) and an adjusted EBITDA loss of DKK 50-60 million (improvement of 22-35%). https://www.inderes.dk/research/bioporto-one-pager-q4-and-new-2026-guidance-reinforce-forward-strategy-momentum?utm_source=nordnet&utm_medium=integration·14.2.Early in the journey? After 15 years, BP is by no means early in any journey, while there are only very few clips left on the punch card..... the patents might expire before results are shown and when the results perhaps come, China will surely be ready with a cheap copy- ·10.2.A brief description of Klaus Juhl Wulff's CV and what main task will rest on his shoulders By Michael FriisHead of Equities 09.02.2026, 08.52 BioPorto BioPorto can this morning announce that they have appointed Klaus Juhl Wulff as new EVP and CFO with commencement no later than May 1, 2026. Klaus Juhl Wulff will simultaneously join the executive management. He comes from a position as CFO at AquaPorin and has more than 20 years of experience within finance, operations, M&A, and capital markets. As part of his area of responsibility, he will get the strategic responsibility for supply chain with the aim of supporting the expected high growth going forward. The Management.·11.2.Are you annoyed that you didn't manage to buy shares while they were cheaper?
·13.2.@3D, Why are you so aggressive here on this forum, where people should ideally be mature and show consideration for each other? We are not all super investors, or members of the millionaire's club. Firstly, my post was not directed at you as a person; if you look at the text again, you can see that I used "du" and not a simple "you" if it were to refer to you as a person. I used "du" to refer to your post, that there is missing information about the person you are referring to. Normally here on the forum, one uses @nickname followed by the text. And secondly: even if what you write about me was true (despite me not having published my portfolio in my profile), since when is it forbidden to express one's opinion about something, even if one does not own shares in the company in question? Maybe I should ask NN if they have given you the right/power as "tsarforum" who should tyrannize everyone else who does not obey your opinions. In that case, I would suggest it gets a new name "The Truth" 
·9.2.The stock expert Lars Hytting from Artha Kapitalforvaltning has today been interviewed by Børsen about the upcoming stock game where he "buys" big time into Bioporto......I am aware that it is for the stock game but I still think he has some interesting short-term and long-term comments about Bioporto and where the company has gotten to now :(And which I strongly agree with ) The first stock that Hytting has chosen to include in the stock game is the Danish biotech company Bioporto. A risky stock, which he assesses can quickly turn around. The stock has fallen 35 pct. in the past year, and the company is currently awaiting approval of a product from the American Food and Drug Administration (FDA). Hytting explains that even if the approval doesn't come through while the stock game is ongoing, even small news about the company could potentially send the stock price soaring. “It's a stock that has been completely beaten down, so if, for example, there's an announcement that they are well on their way with the study, the stock could easily rise 10-20 pct., even if nothing major actually happens,” he says. “It's an interesting stock that has experienced big ups and downs, but which is actually in a good place now. They have a good management and a good board and are relentlessly pursuing this FDA approval. So it's a stock that could actually also be interesting in the long run,” he continues.·11.2.I can in no way recommend it, for this could easily end up as a new First North cadaver, but it would probably have been better if the tip for the game had chosen Stenocare. Small, illiquid and with large fluctuations, and then it has a fan base that is probably under construction and that has not taken a beating in 15 years.- ·9.2.Nominally, I have quite a lot of shares in the company. In terms of value, it's, to say the least, not much. But, strictly speaking, they have exclusively lived off the shareholders' money for decades. I'm staying in it, though, and letting it be my lottery ticket. Although I'm starting to believe that the chance for a good win is greater in Lotto than with Bioporto 😅·9.2.My stance on the current team, to drive BP forward after PME, is that they are competent people for this job, therefore I have bought up continuously, after PME handed over the reins to CB. In other words, I look at what resources are available to drive the company into the future, and not at what happened in the past, when PME had the reins. I am sure that CB has chosen the right person to be his wingman.·9.2.3D You also wrote that in 2024, and again in 2025 and now in 2026. I have probably overlooked your posts from previous years - while PME was in charge....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
91 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13.2.Anyone who is optimistic about bioporto right now? Have been in for over 5 years and have a loss of 75 percent. Feel it's the next one I'll take the loss on, if others agree.
- ·12.2.The stock price, I think, will probably soon be kr. 4,032. But we'll see in the next couple of months.·14.2. · MuokattuIf we look at the last automatic analysis, the signal is that shareholders are a bit pessimistic about this stock, it justifies this by stating that it closed yesterday below one krone. My opinion is that this fits very well, because the new duo must prove their worth and deliver positive results to gain the shareholders' trust. The positive thing is that I can get more shares for cheaper money. Although it is early in the journey, the results and new expectations for 2026 continue to confirm the execution of the "Fremadrettet" strategy. BioPorto aims for a total revenue of DKK 48-58 million for 2026 (growth of 20-45%) and an adjusted EBITDA loss of DKK 50-60 million (improvement of 22-35%). https://www.inderes.dk/research/bioporto-one-pager-q4-and-new-2026-guidance-reinforce-forward-strategy-momentum?utm_source=nordnet&utm_medium=integration·14.2.Early in the journey? After 15 years, BP is by no means early in any journey, while there are only very few clips left on the punch card..... the patents might expire before results are shown and when the results perhaps come, China will surely be ready with a cheap copy
- ·10.2.A brief description of Klaus Juhl Wulff's CV and what main task will rest on his shoulders By Michael FriisHead of Equities 09.02.2026, 08.52 BioPorto BioPorto can this morning announce that they have appointed Klaus Juhl Wulff as new EVP and CFO with commencement no later than May 1, 2026. Klaus Juhl Wulff will simultaneously join the executive management. He comes from a position as CFO at AquaPorin and has more than 20 years of experience within finance, operations, M&A, and capital markets. As part of his area of responsibility, he will get the strategic responsibility for supply chain with the aim of supporting the expected high growth going forward. The Management.·11.2.Are you annoyed that you didn't manage to buy shares while they were cheaper?·13.2.@3D, Why are you so aggressive here on this forum, where people should ideally be mature and show consideration for each other? We are not all super investors, or members of the millionaire's club. Firstly, my post was not directed at you as a person; if you look at the text again, you can see that I used "du" and not a simple "you" if it were to refer to you as a person. I used "du" to refer to your post, that there is missing information about the person you are referring to. Normally here on the forum, one uses @nickname followed by the text. And secondly: even if what you write about me was true (despite me not having published my portfolio in my profile), since when is it forbidden to express one's opinion about something, even if one does not own shares in the company in question? Maybe I should ask NN if they have given you the right/power as "tsarforum" who should tyrannize everyone else who does not obey your opinions. In that case, I would suggest it gets a new name "The Truth"
- ·9.2.The stock expert Lars Hytting from Artha Kapitalforvaltning has today been interviewed by Børsen about the upcoming stock game where he "buys" big time into Bioporto......I am aware that it is for the stock game but I still think he has some interesting short-term and long-term comments about Bioporto and where the company has gotten to now :(And which I strongly agree with ) The first stock that Hytting has chosen to include in the stock game is the Danish biotech company Bioporto. A risky stock, which he assesses can quickly turn around. The stock has fallen 35 pct. in the past year, and the company is currently awaiting approval of a product from the American Food and Drug Administration (FDA). Hytting explains that even if the approval doesn't come through while the stock game is ongoing, even small news about the company could potentially send the stock price soaring. “It's a stock that has been completely beaten down, so if, for example, there's an announcement that they are well on their way with the study, the stock could easily rise 10-20 pct., even if nothing major actually happens,” he says. “It's an interesting stock that has experienced big ups and downs, but which is actually in a good place now. They have a good management and a good board and are relentlessly pursuing this FDA approval. So it's a stock that could actually also be interesting in the long run,” he continues.·11.2.I can in no way recommend it, for this could easily end up as a new First North cadaver, but it would probably have been better if the tip for the game had chosen Stenocare. Small, illiquid and with large fluctuations, and then it has a fan base that is probably under construction and that has not taken a beating in 15 years.
- ·9.2.Nominally, I have quite a lot of shares in the company. In terms of value, it's, to say the least, not much. But, strictly speaking, they have exclusively lived off the shareholders' money for decades. I'm staying in it, though, and letting it be my lottery ticket. Although I'm starting to believe that the chance for a good win is greater in Lotto than with Bioporto 😅·9.2.My stance on the current team, to drive BP forward after PME, is that they are competent people for this job, therefore I have bought up continuously, after PME handed over the reins to CB. In other words, I look at what resources are available to drive the company into the future, and not at what happened in the past, when PME had the reins. I am sure that CB has chosen the right person to be his wingman.·9.2.3D You also wrote that in 2024, and again in 2025 and now in 2026. I have probably overlooked your posts from previous years - while PME was in charge....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
3 654
Myynti
Määrä
13 890
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 346 | - | - | ||
| 250 | - | - | ||
| 5 676 | - | - | ||
| 32 000 | - | - | ||
| 10 000 | - | - |
Ylin
0,992VWAP
Alin
0,962VaihtoMäärä
0,1 152 552
VWAP
Ylin
0,992Alin
0,962VaihtoMäärä
0,1 152 552
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 141 176 | 141 176 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 141 176 | 141 176 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
2025 Q3 -tulosraportti
91 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13.2.Anyone who is optimistic about bioporto right now? Have been in for over 5 years and have a loss of 75 percent. Feel it's the next one I'll take the loss on, if others agree.
- ·12.2.The stock price, I think, will probably soon be kr. 4,032. But we'll see in the next couple of months.·14.2. · MuokattuIf we look at the last automatic analysis, the signal is that shareholders are a bit pessimistic about this stock, it justifies this by stating that it closed yesterday below one krone. My opinion is that this fits very well, because the new duo must prove their worth and deliver positive results to gain the shareholders' trust. The positive thing is that I can get more shares for cheaper money. Although it is early in the journey, the results and new expectations for 2026 continue to confirm the execution of the "Fremadrettet" strategy. BioPorto aims for a total revenue of DKK 48-58 million for 2026 (growth of 20-45%) and an adjusted EBITDA loss of DKK 50-60 million (improvement of 22-35%). https://www.inderes.dk/research/bioporto-one-pager-q4-and-new-2026-guidance-reinforce-forward-strategy-momentum?utm_source=nordnet&utm_medium=integration·14.2.Early in the journey? After 15 years, BP is by no means early in any journey, while there are only very few clips left on the punch card..... the patents might expire before results are shown and when the results perhaps come, China will surely be ready with a cheap copy
- ·10.2.A brief description of Klaus Juhl Wulff's CV and what main task will rest on his shoulders By Michael FriisHead of Equities 09.02.2026, 08.52 BioPorto BioPorto can this morning announce that they have appointed Klaus Juhl Wulff as new EVP and CFO with commencement no later than May 1, 2026. Klaus Juhl Wulff will simultaneously join the executive management. He comes from a position as CFO at AquaPorin and has more than 20 years of experience within finance, operations, M&A, and capital markets. As part of his area of responsibility, he will get the strategic responsibility for supply chain with the aim of supporting the expected high growth going forward. The Management.·11.2.Are you annoyed that you didn't manage to buy shares while they were cheaper?·13.2.@3D, Why are you so aggressive here on this forum, where people should ideally be mature and show consideration for each other? We are not all super investors, or members of the millionaire's club. Firstly, my post was not directed at you as a person; if you look at the text again, you can see that I used "du" and not a simple "you" if it were to refer to you as a person. I used "du" to refer to your post, that there is missing information about the person you are referring to. Normally here on the forum, one uses @nickname followed by the text. And secondly: even if what you write about me was true (despite me not having published my portfolio in my profile), since when is it forbidden to express one's opinion about something, even if one does not own shares in the company in question? Maybe I should ask NN if they have given you the right/power as "tsarforum" who should tyrannize everyone else who does not obey your opinions. In that case, I would suggest it gets a new name "The Truth"
- ·9.2.The stock expert Lars Hytting from Artha Kapitalforvaltning has today been interviewed by Børsen about the upcoming stock game where he "buys" big time into Bioporto......I am aware that it is for the stock game but I still think he has some interesting short-term and long-term comments about Bioporto and where the company has gotten to now :(And which I strongly agree with ) The first stock that Hytting has chosen to include in the stock game is the Danish biotech company Bioporto. A risky stock, which he assesses can quickly turn around. The stock has fallen 35 pct. in the past year, and the company is currently awaiting approval of a product from the American Food and Drug Administration (FDA). Hytting explains that even if the approval doesn't come through while the stock game is ongoing, even small news about the company could potentially send the stock price soaring. “It's a stock that has been completely beaten down, so if, for example, there's an announcement that they are well on their way with the study, the stock could easily rise 10-20 pct., even if nothing major actually happens,” he says. “It's an interesting stock that has experienced big ups and downs, but which is actually in a good place now. They have a good management and a good board and are relentlessly pursuing this FDA approval. So it's a stock that could actually also be interesting in the long run,” he continues.·11.2.I can in no way recommend it, for this could easily end up as a new First North cadaver, but it would probably have been better if the tip for the game had chosen Stenocare. Small, illiquid and with large fluctuations, and then it has a fan base that is probably under construction and that has not taken a beating in 15 years.
- ·9.2.Nominally, I have quite a lot of shares in the company. In terms of value, it's, to say the least, not much. But, strictly speaking, they have exclusively lived off the shareholders' money for decades. I'm staying in it, though, and letting it be my lottery ticket. Although I'm starting to believe that the chance for a good win is greater in Lotto than with Bioporto 😅·9.2.My stance on the current team, to drive BP forward after PME, is that they are competent people for this job, therefore I have bought up continuously, after PME handed over the reins to CB. In other words, I look at what resources are available to drive the company into the future, and not at what happened in the past, when PME had the reins. I am sure that CB has chosen the right person to be his wingman.·9.2.3D You also wrote that in 2024, and again in 2025 and now in 2026. I have probably overlooked your posts from previous years - while PME was in charge....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
3 654
Myynti
Määrä
13 890
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 346 | - | - | ||
| 250 | - | - | ||
| 5 676 | - | - | ||
| 32 000 | - | - | ||
| 10 000 | - | - |
Ylin
0,992VWAP
Alin
0,962VaihtoMäärä
0,1 152 552
VWAP
Ylin
0,992Alin
0,962VaihtoMäärä
0,1 152 552
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 141 176 | 141 176 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 141 176 | 141 176 | 0 | 0 |